AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28960596 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stress (loss of interest)
Number of subjects: 14577
Study 28960596 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stress (financial stress)
Number of subjects: 14577
Study 28960596 — intervention group
Group type: EXPERIMENTAL
Intervention: Living alone
Number of subjects: 14577
Study 28960596 — intervention group
Group type: EXPERIMENTAL
Intervention: Being married vs being widowed
Number of subjects: 14577
Study 27394149 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral Docosahexaenoic Acid (DHA)
Number of subjects: 34
Study 27394149 — intervention group
Group type: COMPARATOR
Intervention: Sunflower Oil (SO)
Number of subjects: 34
Study 24596360 — intervention group
Group type: COMPARATOR
Intervention: Control group from the BREX study (Group 1)
Number of subjects: 0
Study 24596360 — intervention group
Group type: COMPARATOR
Intervention: Follow-up patients not participating in any intervention study (Group 2)
Number of subjects: 0
Study 22551252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group intervention
Number of subjects: 242
Study 22551252 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical practice (Control)
Number of subjects: 242
Study 20636466 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention of four half-day workshops
Number of subjects: 163
Study 18372701 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 24
Study 18372701 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition
Number of subjects: 24
Study 18372701 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 15859528 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) treatment of the lower extremity
Number of subjects: 11
Study 12602111 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed magnetic field therapy
Number of subjects: 36
Study 12602111 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 36
Study 10749028 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (n = 12 in each subgroup)
Number of subjects: 50
Study 10749028 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 13 in each group)
Number of subjects: 50
Study 7582337 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet-to-dry saline gauze dressings changed twice a day
Number of subjects: 0
Study 7582337 — intervention group
Group type: COMPARATOR
Intervention: Hydrocolloid dressing (HCD) DuoDERM changed when needed or once a week
Number of subjects: 0
Study 1660009 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 10,000 anti Xa units of LMWH
Number of subjects: 16
Study 1660009 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic administration before clamping of 10,000 anti Xa units of LMWH
Number of subjects: 16
Study 1660009 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic administration of 10,000 anti Xa units of LMWH
Number of subjects: 16
Study 1660009 — intervention group
Group type: COMPARATOR
Intervention: Aortic injection after clamping of 10,000 anti Xa units of LMWH
Number of subjects: 16
Study 7073642 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed mood induction
Number of subjects: 68
Study 7073642 — intervention group
Group type: COMPARATOR
Intervention: Neutral mood induction
Number of subjects: 68
Study 7073642 — intervention group
Group type: COMPARATOR
Intervention: Elated mood induction
Number of subjects: 68
Study 7073642 — intervention group
Group type: EXPERIMENTAL
Intervention: High weight-fluctuation factor
Number of subjects: 68
Study 7073642 — intervention group
Group type: COMPARATOR
Intervention: Concern for dieting factor
Number of subjects: 68
Study 31567801 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Decision Aid (short DA)
Number of subjects: 1220
Study 31567801 — intervention group
Group type: COMPARATOR
Intervention: Long Decision Aid (long DA)
Number of subjects: 1220
Study 31567801 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DA groups (short DA and long DA)
Number of subjects: 1220
Study 31567801 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon group with patient preference report
Number of subjects: 1220
Study 31567801 — intervention group
Group type: COMPARATOR
Intervention: Usual care surgeon group
Number of subjects: 1220
Study 26940348 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual services plus a 3-day manualized risk detection intervention
Number of subjects: 74
Study 26940348 — intervention group
Group type: COMPARATOR
Intervention: Usual case management services
Number of subjects: 74
Study 26778165 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral β blockers (administered ≤24 hours after hospital admission)
Number of subjects: 5259
Study 26778165 — intervention group
Group type: COMPARATOR
Intervention: Delayed oral β blockers (administered >24 hours after hospital admission)
Number of subjects: 5259
Study 25484042 — intervention group
Group type: EXPERIMENTAL
Intervention: ch‐mAb7F9, doses of 0.2 to 20 mg/kg
Number of subjects: 42
Study 25484042 — intervention group
Group type: COMPARATOR
Intervention: Placebo (implied control group)
Number of subjects: 42
Study 22301525 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDCAP (Newborn Individualized Developmental Care and Assessment Program)
Number of subjects: 30
Study 22301525 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 30
Study 18839190 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided steroid injections
Number of subjects: 27
Study 18839190 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpation-guided steroid injections
Number of subjects: 27
Study 18839190 — intervention group
Group type: EXPERIMENTAL
Intervention: Scintigraphy-guided steroid injections
Number of subjects: 27
Study 18839190 — intervention group
Group type: COMPARATOR
Intervention: Comparison among ultrasound-guided, palpation-guided, and scintigraphy-guided injections
Number of subjects: 27
Study 17166311 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation protocol
Number of subjects: 0
Study 15164322 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/d)
Number of subjects: 40
Study 15164322 — intervention group
Group type: COMPARATOR
Intervention: Control group (hypolipidic diet)
Number of subjects: 40
Study 11494621 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% carbamide peroxide
Number of subjects: 60
Study 11494621 — intervention group
Group type: COMPARATOR
Intervention: 10% carbamide peroxide
Number of subjects: 60
Study 9771053 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 20
Study 8276367 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (0.4 U/min)
Number of subjects: 28
Study 8276367 — intervention group
Group type: EXPERIMENTAL
Intervention: Glypressin (2-mg injection)
Number of subjects: 28
Study 8276367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 2735328 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate 2 g at night
Number of subjects: 117
Study 2735328 — intervention group
Group type: EXPERIMENTAL
Intervention: cimetidine 400 mg
Number of subjects: 117
Study 2735328 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 117
Study 1172718 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin sodium added to chemotherapy
Number of subjects: 128
Study 1172718 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase with surgery of tumors of the large bowel
Number of subjects: 128
Study 1172718 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinase
Number of subjects: 128
Study 31911640 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced FEV1
Number of subjects: 29266
Study 31911640 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced FEV1/FVC
Number of subjects: 29266
Study 31911640 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced FEV1/FVC in never smokers
Number of subjects: 29266
Study 31220851 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted lung denervation (TLD) at 32 W
Number of subjects: 30
Study 31220851 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted lung denervation (TLD) at 29 W
Number of subjects: 30
Study 31220851 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of TLD (29 W and 32 W)
Number of subjects: 30
Study 31220851 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label confirmation phase study
Number of subjects: 30
Study 26055693 — intervention group
Group type: EXPERIMENTAL
Intervention: New reduced-dose Td vaccine
Number of subjects: 164
Study 26055693 — intervention group
Group type: COMPARATOR
Intervention: Commercially available Td vaccine
Number of subjects: 164
Study 26130075 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking Away group - structured education programme with annual maintenance sessions
Number of subjects: 0
Study 26130075 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking Away Plus group - structured education programme with annual maintenance sessions, plus follow-on support through text-messaging and telephone calls
Number of subjects: 0
Study 26130075 — intervention group
Group type: COMPARATOR
Intervention: Control group - detailed advice leaflet
Number of subjects: 0
Study 23460567 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Brice interview (postoperative day 28-30)
Number of subjects: 18847
Study 23460567 — intervention group
Group type: COMPARATOR
Intervention: Quality assurance data (postoperative day 1)
Number of subjects: 18847
Study 21114896 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Control (CC) task
Number of subjects: 59
Study 21114896 — intervention group
Group type: COMPARATOR
Intervention: Peripheral Vision (PV) comparison task
Number of subjects: 59
Study 18289563 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg intravenous papaverine hydrochloride
Number of subjects: 86
Study 18289563 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg intramuscular sodium diclofenac
Number of subjects: 86
Study 18289563 — intervention group
Group type: EXPERIMENTAL
Intervention: papaverine hydrochloride plus sodium diclofenac
Number of subjects: 86
Study 16048734 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (ZOL) 10 mg orally
Number of subjects: 14
Study 16048734 — intervention group
Group type: COMPARATOR
Intervention: Brotizolam (BTM) 0.25 mg orally
Number of subjects: 14
Study 12480612 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin solution for inhalation, 300 mg, twice daily for 28 days
Number of subjects: 21
Study 12480612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 11190906 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg of aspirin every third day
Number of subjects: 109
Study 11190906 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg of aspirin every day
Number of subjects: 109
Study 11190906 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg of aspirin every third day
Number of subjects: 109
Study 11190906 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of aspirin every third day
Number of subjects: 109
Study 11190906 — intervention group
Group type: COMPARATOR
Intervention: Placebo every day
Number of subjects: 109
Study 11190906 — intervention group
Group type: COMPARATOR
Intervention: Placebo on other days
Number of subjects: 109
Study 9287403 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 177
Study 9287403 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 177
Study 8422561 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormezanone 400 mg nocte
Number of subjects: 42
Study 8422561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 3018561 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens
Number of subjects: 6
Study 3018561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29466862 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-HBV coinfected patients with high HBV-DNA replication
Number of subjects: 808
Study 29466862 — intervention group
Group type: COMPARATOR
Intervention: HIV-HBV coinfected patients with high HBV-DNA replication, HIV-HBV coinfected patients with low HBV-DNA replication, HIV monoinfection
Number of subjects: 808
Study 28822879 — intervention group
Group type: EXPERIMENTAL
Intervention: CT + Memory Support Intervention
Number of subjects: 48
Study 28822879 — intervention group
Group type: COMPARATOR
Intervention: CT-as-usual
Number of subjects: 48
Study 25564105 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term medication-assisted treatment (ST-MAT) with buprenorphine/naloxone (BUP/NX) for 1 year, including 2 opportunities for a 15-day detoxification and up to 21 sessions of behavioral drug and risk counseling
Number of subjects: 1251
Study 25564105 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term medication-assisted treatment (LT-MAT) with buprenorphine/naloxone (BUP/NX) for 48 weeks, including thrice-weekly dosing and up to 21 counseling sessions
Number of subjects: 1251
Study 25564105 — intervention group
Group type: COMPARATOR
Intervention: Both ST-MAT and LT-MAT
Number of subjects: 1251
Study 23529671 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperprolactinemic women
Number of subjects: 81
Study 23529671 — intervention group
Group type: COMPARATOR
Intervention: Healthy premenopausal women
Number of subjects: 81
Study 21112449 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment program focused on weight loss
Number of subjects: 203
Study 21112449 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment program focused on both weight loss and depression
Number of subjects: 203
Study 21112449 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 203
Study 21112449 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in depression and change in weight
Number of subjects: 203
Study 18242455 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaxial microincision cataract surgery (MICS)
Number of subjects: 50
Study 18242455 — intervention group
Group type: COMPARATOR
Intervention: Conventional coaxial cataract surgery
Number of subjects: 50
Study 16612281 — intervention group
Group type: EXPERIMENTAL
Intervention: Tac
Number of subjects: 46
Study 16612281 — intervention group
Group type: COMPARATOR
Intervention: CyA
Number of subjects: 46
Study 15663227 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel release (CTR)
Number of subjects: 40
Study 15663227 — intervention group
Group type: COMPARATOR
Intervention: Open carpal tunnel release (CTR)
Number of subjects: 40
Study 11041470 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (UK)
Number of subjects: 27
Study 11041470 — intervention group
Group type: COMPARATOR
Intervention: Heparinized saline (HS)
Number of subjects: 27
Study 9310604 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (filgrastim) therapy
Number of subjects: 40
Study 8418721 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 microgram/kg isoproterenol
Number of subjects: 44
Study 8418721 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075 microgram/kg isoproterenol
Number of subjects: 44
Study 8418721 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 44
Study 3543342 — intervention group
Group type: EXPERIMENTAL
Intervention: Butoconazole vaginal cream
Number of subjects: 0
Study 3543342 — intervention group
Group type: COMPARATOR
Intervention: Miconazole nitrate
Number of subjects: 0
Study 3543342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30129320 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral approach (Yeung's technology) in group A (42 cases)
Number of subjects: 165
Study 30129320 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal endoscopic spine system (TESSYS) technology in group B (40 cases)
Number of subjects: 165
Study 30129320 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved transforaminal endoscopic access (ITEA) technology in group C (43 cases)
Number of subjects: 165
Study 30129320 — intervention group
Group type: COMPARATOR
Intervention: Interlaminar approach in group D (40 cases)
Number of subjects: 165
Study 27413037 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure medication regimen (intense treatment)
Number of subjects: 321
Study 27413037 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher blood pressure and treatment with a β‐blocker or randomized to valsartan
Number of subjects: 321
Study 27413037 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic pathogenesis, more dilated left ventricle, and detectable hs‐troponin
Number of subjects: 321
Study 27413037 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery of EF to >40%
Number of subjects: 321
Study 24820121 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement physiotherapy
Number of subjects: 76
Study 23036216 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐TOKE program
Number of subjects: 245
Study 23036216 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (Control)
Number of subjects: 245
Study 20670760 — intervention group
Group type: COMPARATOR
Intervention: Enrollment from lower-risk countries
Number of subjects: 2136
Study 20670760 — intervention group
Group type: COMPARATOR
Intervention: Enrollment from higher-risk countries
Number of subjects: 2136
Study 20670760 — intervention group
Group type: EXPERIMENTAL
Intervention: General clinical site diversity
Number of subjects: 2136
Study 18662494 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 18
Study 18662494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11515716 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Med-100, 350 mg x 2 daily for two months
Number of subjects: 0
Study 11515716 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 0
Study 9196675 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical blur (defocus)
Number of subjects: 0
Study 8199610 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge days
Number of subjects: 47
Study 8199610 — intervention group
Group type: COMPARATOR
Intervention: Nonbinge days
Number of subjects: 47
Study 3540070 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 111
Study 3540070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 29614521 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg twice daily or intravenous argatroban
Number of subjects: 94
Study 29614521 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous enoxaparin 40 mg once daily
Number of subjects: 94
Study 28624677 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management condition with group exercise classes
Number of subjects: 222
Study 28624677 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 222
Study 24709121 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 36
Study 24709121 — intervention group
Group type: COMPARATOR
Intervention: Wait list
Number of subjects: 36
Study 24427665 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (5 µg/Kg)
Number of subjects: 80
Study 24427665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 21372624 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Treatment (CBT)
Number of subjects: 77
Study 21372624 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised Hypnosis
Number of subjects: 77
Study 21372624 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised Hypnosis
Number of subjects: 77
Study 21372624 — intervention group
Group type: COMPARATOR
Intervention: General Anaesthesia (GA)
Number of subjects: 77
Study 19032137 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib
Number of subjects: 100
Study 19032137 — intervention group
Group type: COMPARATOR
Intervention: best supportive care (BSC)
Number of subjects: 100
Study 19032137 — intervention group
Group type: COMPARATOR
Intervention: sorafenib vs. BSC
Number of subjects: 100
Study 16798298 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (32F drain placed anteriorly and 16F thin drain placed retrocardially)
Number of subjects: 140
Study 16798298 — intervention group
Group type: COMPARATOR
Intervention: Group B (32F drain placed anteriorly only)
Number of subjects: 140
Study 16798298 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 140
Study 16798298 — intervention group
Group type: COMPARATOR
Intervention: Group B
Number of subjects: 140
Study 14966578 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% cetylpyridinium chloride (CPC) rinse
Number of subjects: 0
Study 14966578 — intervention group
Group type: COMPARATOR
Intervention: Complex hibitane rinse (Control)
Number of subjects: 0
Study 10634816 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (10 mg/d for 2 weeks)
Number of subjects: 20
Study 10634816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9362716 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese version of the Nurse Stress Checklist (NSC)
Number of subjects: 138
Study 1556522 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening insulin therapy (Monotard HM or Ultratard HM), initial dose 10-16 U, mean dose 23 U d‐1 at 12 months
Number of subjects: 17
Study 1556522 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening insulin therapy
Number of subjects: 17
Study 30822629 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week educational program on CSA self-protection strategies (Group 1)
Number of subjects: 0
Study 30822629 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week educational program on CSA self-protection strategies (Group 2)
Number of subjects: 0
Study 30822629 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study 29545530 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac as PCIA (NSAIDS group)
Number of subjects: 70
Study 29545530 — intervention group
Group type: COMPARATOR
Intervention: Morphine infusion as PCIA (morphine group)
Number of subjects: 70
Study 29545530 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 29545530 — intervention group
Group type: EXPERIMENTAL
Intervention: Both open RC and robot RC cases
Number of subjects: 70